Exponential growth in the first six month of 2020
Oslo, Norway (15 July 2020) Followed by an extremely strong first quarter, NattoPharma further increased revenues in the second quarter by 61%, bringing the YTD growth to 81% compared to the first half in 2019. YTD Adjusted EBITDA came in at NOK 16,7 million. (NOK mill. / %) Q2'20 Q2'19 YTD'20 YTD'19Operating Revenue 48.4 30.0 104.6 57.8EBITDA (adj.) 6.2 0.9 16.7 2.8EBITDA (adj.) margin 12.9 % 3.0 % 16.0 % 4.8 % CEO, Kjetil Ramsøy: “We are proud to announce another strong quarter and a very strong performance year to date. With a